AUS
NZ
UK
CA
USA
IND
Healthcare
ASX Compliance Action Puts Spotlight on OncoSil Securities
March 11, 2026 05:25 PM AEDT| By SamExchange oversight temporarily paused quotation of a specialised healthcare security class, highlighting the importance of listing rule compliance, transparency, and structured governance within Australia’s regulated public market environment.
Imugene Capital Raise Drives Azer-Cel Cancer Program Forward
March 11, 2026 05:22 PM AEDT| By SamImugene Ltd launches a major capital raise to support azer-cel cancer therapy development, expand clinical trials, and strengthen its immuno-oncology pipeline while advancing research within Australia’s biotechnology sector.
Clarity Pharma’s New Share Move Grabs ASX Attention
March 11, 2026 04:20 PM AEDT| By SamA biotechnology company’s new share quotation request highlights ongoing capital activity within Australia’s healthcare innovation sector while reflecting the strategic role equity instruments play in supporting research and development programs.
Biotech Momentum on ASX: Could This Medical Tech Story Surge?
March 11, 2026 12:37 PM AEDT| By SamMetal Powder Works has introduced additional ordinary shares for quotation on the ASX, expanding its capital base and illustrating how evolving capital structures influence liquidity and trading activity.
Imugene Trial Update Sparks Hope in Cancer Immunotherapy
March 10, 2026 07:42 PM AEDT| By SamImugene’s experimental immunotherapy gains attention after a trial participant enters remission. The development highlights progress in advanced lymphoma research and evolving cancer treatment approaches.
CleanSpace Share Quotation Update Highlights ASX Market
March 10, 2026 06:10 PM AEDT| By SamA listed safety technology company applied for quotation of additional ordinary shares, reflecting routine compliance with exchange regulations while highlighting ongoing developments within Australia’s evolving public market landscape.
4DMedical’s Next Chapter: Can Innovation Reshape Market Confidence?
March 10, 2026 05:38 PM AEDT| By SamHealthcare technology companies continue shaping Australia’s market landscape as innovation in respiratory imaging and medical diagnostics attracts attention for its potential role in improving clinical insights and treatment pathways.
Lung Imaging Story: What’s Next for 4DMedical?
March 10, 2026 05:19 PM AEDT| By Sam4DMedical’s latest financial update highlights stable revenue but rising losses, shifting investor attention toward technology adoption, funding resilience, and the evolving role of advanced lung imaging in respiratory healthcare innovation.
Imugene Azer-Cel Trial Sparks Hope in Blood Cancer Fight
March 10, 2026 04:30 PM AEDT| By SamImugene’s azer-cel immunotherapy gains attention after a remission case in its clinical trial. The CAR-T therapy program is advancing research for difficult-to-treat blood cancers across global study sites.
Dimerix Advances Within the All Ordinaries Biotech Space
March 10, 2026 02:00 PM AEDT| By SamDimerix completes adult dosing in its ACTION3 phase trial, with enrolment surpassing target, reinforcing its progress within the All Ordinaries biotech sector.
Why Did the ASX Healthcare Sector Shift Midday Within the ASX 200 Market?
March 10, 2026 01:45 PM AEDT| By SamAustralia’s healthcare sector recorded varied midday activity within the ASX market as biotechnology, pharmaceutical, and medical technology companies remained active across benchmark indices.
CSL Limited Movement Draws Attention in ASX 200 Healthcare Segment
March 10, 2026 01:12 PM AEDT| By SamCSL Limited’s recent movement highlights how earnings updates can influence healthcare sector sentiment within the ASX 300 and ASX All Ords.
ASX 200 Healthcare Stock Surges Amid Market Rotation
March 10, 2026 12:56 PM AEDT| By SamAn ASX 200 healthcare stock climbs strongly as sector rotation supports defensive names within the ASX 300 and All Ordinaries.
Neuren Pharmaceuticals Slides Amid ASX 300 Healthcare Volatility
March 10, 2026 12:27 PM AEDT| By SamNeuren Pharmaceuticals declines following earnings, reflecting valuation recalibration within the ASX 300 and ASX All Ords healthcare segment.
Nanosonics Advances CORIS Platform After US Clearance
March 09, 2026 07:21 PM AEDT| By SamNanosonics advances its CORIS platform after US regulatory clearance expands endoscope compatibility. The development highlights progress in infection-prevention technology and strengthens the company’s position in hospital sterilisation innovation.
Clinuvel Earnings Insight: What It Signals for ASX Healthcare
March 09, 2026 03:59 PM AEDT| By SamClinuvel Pharmaceuticals earnings update has triggered fresh valuation discussion across Australia’s biotechnology sector, highlighting product concentration dynamics and the evolving outlook for specialised healthcare innovation.
Clinuvel Pharmaceuticals Strengthens Profile Within ASX All Ords
March 09, 2026 01:16 PM AEDT| By SamClinuvel Pharmaceuticals maintains its position within the ASX All Ords, reflecting its role in Australia’s biotechnology and healthcare sector landscape.
ASX Market Update: Is Telix Advancing Its AI Imaging Strategy Within the ASX 200?
March 06, 2026 06:36 PM AEDT| By SamTelix advances AI-driven prostate imaging and outlines revenue expectations, reinforcing its role in healthcare innovation within the ASX 200.
HitIQ Seeks ASX Quotation for New Shares and Options
March 06, 2026 04:45 PM AEDT| By SamAn Australian sports technology company expands its capital structure through quotation of new securities, supporting development of wearable monitoring devices and advanced analytics for improved athlete safety and performance insights.
HitIQ Director Fee Share Move Signals Governance Strategy
March 06, 2026 04:26 PM AEDT| By SamA governance update highlights how an Australian technology company manages capital structure while advancing innovation in sports safety monitoring, reflecting broader trends shaping emerging businesses across the exchange.
Advertise your brand on Kalkine Media